← 返回前沿论文

靶向自噬克服 B 细胞恶性肿瘤中肿瘤内在的 CAR-T 免疫治疗耐药

英文原题:Targeting autophagy overcomes cancer-intrinsic resistance to CAR-T immunotherapy in B-cell malignancies.

PubMed 2024/02/26(内容时间) Cancer Commun (Lond) Q1 · IF 28.4(JCR 2025)

研究概要

这些发现证实,B细胞恶性肿瘤中的自噬信号对于CAR-T细胞的有效细胞毒性功能至关重要,从而为开发靶向自噬的策略以提高CAR-T细胞免疫疗法的临床疗效铺平了道路。

研究思路结论见上方概要

CAR-T(CAR-T)细胞疗法已显著革新了血液系统恶性肿瘤患者的临床结局,但导致CAR-T细胞耐药的肿瘤内在机制仍未完全阐明。本研究旨在探索癌细胞对CAR-T细胞介导杀伤敏感性的分子决定因素,并更好地理解其潜在机制及可能通过调控提高临床疗效。

通过人全基因组CRISPR/Cas9敲除筛选,鉴定使癌细胞逃避CD19 CAR-T细胞杀伤的关键基因。进一步通过体外细胞毒性实验以及肿瘤组织和骨髓标本评估,证实关键基因在癌细胞对CAR-T细胞敏感性中的作用。此外,在小鼠和细胞模型中阐明了影响CAR-T细胞介导肿瘤清除的具体机制。

基于 CRISPR/Cas9 的敲除筛选显示,自噬相关基因(ATG3、BECN1 和 RB1CC1)的富集可保护癌细胞免受 CD19 CAR-T 细胞介导的细胞毒性作用。这些发现在对自噬进行遗传学和药理学抑制的细胞中通过体外细胞毒性试验得到进一步验证。值得注意的是,肿瘤样本中这三种自噬相关蛋白的较高表达与复发/难治性 B 细胞淋巴瘤患者在接受 CD19 CAR-T 治疗后的较差缓解和更差生存相关。对 B 细胞白血病患者骨髓样本的 bulk RNA 测序分析也提示,自噬与 CD19 CAR-T 细胞治疗后的治疗反应和复发具有临床相关性。药理学抑制自噬和敲除 RB1CC1 可在 B 细胞白血病和淋巴瘤小鼠模型中显著增敏肿瘤细胞,使其对 CD19 CAR-T 细胞介导的杀伤更敏感。此外,我们的研究揭示,肿瘤内在的自噬通过 TNF- -TNFR1 轴介导的凋亡以及 STAT1/IRF1 诱导的趋化因子信号激活,介导 CAR-T 细胞逃逸。

展开英文摘要原文

BACKGROUND: Chimeric antigen receptor T (CAR-T) therapy has substantially revolutionized the clinical outcomes of patients with hematologic malignancies, but the cancer-intrinsic mechanisms underlying resistance to CAR-T cells remain yet to be fully understood. This study aims to explore the molecular determinants of cancer cell sensitivity to CAR-T cell-mediated killing and to provide a better understanding of the underlying mechanisms and potential modulation to improve clinical efficacy. METHODS: The human whole-genome CRISPR/Cas9-based knockout screening was conducted to identify key genes that enable cancer cells to evade CD19 CAR-T-cell-mediated killing. The in vitro cytotoxicity assays and evaluation of tumor tissue and bone marrow specimens were further conducted to confirm the role of the key genes in cancer cell susceptibility to CAR-T cells. In addition, the specific mechanisms influencing CAR-T cell-mediated cancer clearance were elucidated in mouse and cellular models. RESULTS: The CRISPR/Cas9-based knockout screening showed that the enrichment of autophagy-related genes (ATG3, BECN1, and RB1CC1) provided protection of cancer cells from CD19 CAR-T cell-mediated cytotoxicity. These findings were further validated by in vitro cytotoxicity assays in cells with genetic and pharmacological inhibition of autophagy. Notably, higher expression of the three autophagy-related proteins in tumor samples was correlated with poorer responsiveness and worse survival in patients with relapsed/refractory B-cell lymphoma after CD19 CAR-T therapy. Bulk RNA sequencing analysis of bone marrow samples from B-cell leukemia patients also suggested the clinical relevance of autophagy to the therapeutic response and relapse after CD19 CAR-T cell therapy. Pharmacological inhibition of autophagy and knockout of RB1CC1 could dramatically sensitize tumor cells to CD19 CAR-T cell-mediated killing in mouse models of both B-cell leukemia and lymphoma. Moreover, our study revealed that cancer-intrinsic autophagy mediates evasion of CAR-T cells via the TNF- -TNFR1 axis-mediated apoptosis and STAT1/IRF1-induced chemokine signaling activation. CONCLUSIONS: These findings confirm that autophagy signaling in B-cell malignancies is essential for the effective cytotoxic function of CAR-T cells and thereby pave the way for the development of autophagy-targeting strategies to improve the clinical efficacy of CAR-T cell immunotherapy.

论文信息

作者
Tang L、Zhang H、Zhou F、Wei Q、Du M、Wu J、Li C、Luo W
单位
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P. R. China.China
文献类型
非美国政府资助研究
期刊
Cancer communications (London, England)2024 Mar
原文标识
PubMed 38407943 · DOI 10.1002/cac2.12525